All News

Secretary Kennedy explained that nearly $500 million in contracts will be canceled.

The talks are a result of the MFN order, which seeks to make US drug prices match lower prices in international markets.

A new two-phase initiative aims to streamline facility approvals, reduce reliance on foreign pharmaceutical production, and bolster domestic supply chain resilience amid rising tariffs and reshoring investments.

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.

Eli Lilly’s investigational, once-daily oral GLP-1 receptor agonist orforglipron produced a 12% body weight reduction in a Phase III trial, slightly lower than Novo Nordisk’s Wegovy.

The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 outlook on the strength of key pharmaceutical products.

Modeyso is the first and only approved treatment for recurrent H3 K27M-mutant diffuse midline glioma in patients aged one year and older.

XtalPi and DoveTree collaborate on a groundbreaking $6 billion drug discovery partnership, merging AI technology with biological expertise to tackle complex diseases.

Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the public domain.

The industry is facing calls to reduce prices while also bracing for increased tariffs.

Celltrion's Avtozma IV gains FDA approval for treating cytokine release syndrome, enhancing treatment options for patients aged 2 and older.

Ajovy becomes the first-and-only calcitonin gene-related peptide agonist approved for pediatric patients aged six to 17 years with episodic migraine who weigh at least 99 lbs.

The deal brings the FDA-approved neuroblastoma therapy Danyelza (naxitamab-gqgk) to SERB Pharmaceuticals and advances its expansion in rare and pediatric oncology.

The move comes amidst a turbulent time at HHS.

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co-pay for a specific product.

Explore how Wounded Warrior Project and advocates like Morgan Fox promote mental health awareness and support for veterans facing PTSD and depression.

The choice reflects the company's aims to revolutionize chronic care and expand global health solutions through innovative technology.

Gene Mack, CEO, GAIN Therapeutics, highlights early Phase Ib data showing GT-02287 may enhance neuroprotection across a wider spectrum of Parkinson’s patients regardless of genetic status.

The AI-driven collaboration will use Syntekabio’s DeepMatcher platform to identify new therapeutic targets for MetaVia’s DA-1241 following promising Phase IIa trial (NCT06054815) results in patients with presumed metabolic dysfunction-associated steatohepatitis.

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit over placebo in post-bunionectomy surgical pain relief.

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed that patients treated with Breyanzi for relapsed or refractory marginal zone lymphoma demonstrated strong and lasting responses.

A Harvard Business School Healthcare Alumni Association Q&A with Stephanie J. Creary, Assistant Professor of Management at The Wharton School of The University of Pennsylvania.

Despite missing the primary endpoint, SB-01 demonstrated durable clinical improvements and consistent results in the Phase III MODEL trial (NCT05516992), reinforcing its potential as a non-surgical treatment for chronic low back pain associated with degenerative disc disease.

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined outpatient regimen aimed at accelerating enrollment and regulatory review in the Phase II ALPHA3 trial (NCT06500273).

Gene Mack, CEO, GAIN Therapeutics, outlines how early trial results for GT-02287 are shaping the company’s strategy for advancing a potential new treatment for Parkinson’s disease.

Organizations commonly navigate outdated systems that make collaboration harder and breakthroughs slower, causing delays, missed insights, and costly rework.

Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.

Members of the industry believe the US should remain an innovation-friendly market.